Clinical Trials Logo
  1. Home
  2. Malignant Solid Neoplasm
  3. NCT06062901
  4. Details
NCT06062901 Clinical Trial

An Educational Intervention on Provider Knowledge for the Support of Cancer Survivors

Malignant Solid Neoplasm Clinical Trial

Official title:
Survivorship ECHO Project

Clinical Trial Details — Status: Active, not recruiting

Administrative data
NCT number NCT06062901
Other study ID # OSU-21149
Secondary ID NCI-2021-06471
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date September 17, 2021
Est. completion date December 31, 2024

Study information
Verified date March 2024
Source Ohio State University Comprehensive Cancer Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This clinical trial utilizes the Project Extension for Community Healthcare Outcomes (ECHO) model to recruit, train, and support community healthcare providers in cancer survivorship best practices. Cancer survivors have distinct medical needs and are more likely to report being in poor or fair overall health compared to those who do not report a history of cancer. There is a lack of educational opportunities focused on survivorship care for health providers. Although progress has been made with the development of survivorship guidelines, physicians continue to express barriers to addressing concerns of cancer survivors. This study is to utilize a Survivorship ECHO education intervention to assess its effects on provider knowledge and comfort with survivorship guidelines as well as greater adherence to guideline concordant breast cancer survivorship care recommendations.

Description:

PRIMARY OBJECTIVES: I. Determine the effectiveness of the Survivorship ECHO's platform by assessing provider knowledge of cancer survivorship best practices using pre- and post-enrollment surveys. II. Evaluate implementation of survivorship best practices into clinical practice and documentation after enrollment in our Survivorship ECHO. OUTLINE: Participants attend 6 sessions of Survivorship ECHO educational intervention over 1 hour each, every 2 weeks for 12 weeks. Participants may optionally participate in a one-on-one interview to give feedback about the sessions over 30 minutes.

Recruitment information / eligibility
Status Active, not recruiting
Enrollment 28
Est. completion date December 31, 2024
Est. primary completion date September 19, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: - Providers from The James Cancer Network (consists of five community sites in Ohio: St. Rita's Memorial Center, Memorial Health, Madison Health, Wooster Community Hospital, and Clinton Memorial Hospital) - Eligible participants will include registered nurses, advanced practice registered nurses, physician assistants, nutritionists, radiation oncologists and oncologists

Study Design

Related Conditions & MeSH terms

Intervention

Other:
• Educational Intervention
Receive educational intervention
• Interview
Participate in one-on-one interview
• Survey Administration
Ancillary studies

Locations
Country Name City State
United States Ohio State University Comprehensive Cancer Center Columbus Ohio

Sponsors (1)
Lead Sponsor Collaborator
Ohio State University Comprehensive Cancer Center

Country where clinical trial is conducted

United States, 

Outcome
Type Measure Description Time frame Safety issue
Primary Change in level of understanding in key survivorship knowledge areas Includes knowledge on surveillance, late and long-term effects of chemotherapy, health promotion, disease prevention and psychosocial evaluation and support. A Likert survey will assess provider comfort and knowledge with core cancer survivorship competencies with higher scores associated with higher levels of knowledge and comfort. Baseline up to study completion, typically 1 year
Primary Met and unmet needs Content, participant needs, and aspects of delivering the Survivorship ECHO platform explored using qualitative analysis. Up to study completion, typically 1 year
Primary Acceptability of current structure Content, participant needs, and aspects of delivering the Survivorship ECHO platform explored using qualitative analysis. Up to study completion, typically 1 year
Primary Barriers to accessing ECHO Content, participant needs, and aspects of delivering the Survivorship ECHO platform explored using qualitative analysis. Up to study completion, typically 1 year
See also
  Status Clinical Trial Phase
Recruiting NCT06030427 - Virtual Mindfulness and Weight Management to Mitigate Risk of Relapse and Improve Wellbeing in Cancer Survivors N/A
Completed NCT04337203 - Shared Healthcare Actions and Reflections Electronic Systems in Survivorship N/A
Recruiting NCT05660421 - Itacitinib for the Treatment Steroid Refractory Immune Related Adverse Events Arising From Immune Checkpoint Inhibitors Phase 2
Suspended NCT04060849 - Nozin in Preventing Respiratory Viral Infections in Patients Undergoing Stem Cell Transplant, PREV-NOSE STUDY Phase 1
Recruiting NCT06192875 - A Novel Molecular Approach to Blood DNA Screening for Cancer: Specificity Assessment (The NOMAD Study)
Completed NCT04122118 - Pharmacist-led Transitions of Care in the Outpatient Oncology Infusion Center for Patients With Solid Tumor N/A
Active, not recruiting NCT04940299 - Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma Phase 2
Active, not recruiting NCT03168737 - 18F-Fluoroazomycin Arabinoside PET-CT in Diagnosing Solid Tumors in Patients Phase 1
Active, not recruiting NCT02444741 - Pembrolizumab and Stereotactic Body Radiation Therapy or Non-Stereotactic Wide-Field Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer Phase 1/Phase 2
Terminated NCT04081298 - eHealth Diet and Physical Activity Program for the Improvement of Health in Rural Latino Cancer Survivors N/A
Active, not recruiting NCT04555837 - Alisertib and Pembrolizumab for the Treatment of Patients With Rb-deficient Head and Neck Squamous Cell Cancer Phase 1/Phase 2
Completed NCT04983901 - PHASE II SINGLE-CENTER, RANDOMIZED, OPEN-LABEL, PROSPECTIVE, STUDY TO DETERMINE THE IMPACT OF SERIAL PROCALCITONIN Phase 2
Active, not recruiting NCT04602026 - The RIOT Trial: Re-Defining Frailty and Improving Outcomes With Prehabilitation for Pancreatic, Liver, or Gastric Cancer N/A
Recruiting NCT04871542 - Immune Checkpoint Inhibitor Toxicity Risk Prediction in Solid Tumors
Active, not recruiting NCT04592250 - Financial Toxicity in Cancer Patients
Recruiting NCT05112614 - Role of Gut Microbiome in Cancer Therapy
Active, not recruiting NCT04296305 - Effect of Opioid Infusion Rate on Abuse Liability Potential of Intravenous Hydromorphone for Cancer Pain Phase 4
Recruiting NCT05873608 - Communication Issues in Patient and Provider Discussions of Immunotherapy N/A
Recruiting NCT02464696 - Non-invasive Ventilation in Reducing the Need for Intubation in Patients With Cancer and Respiratory Failure N/A
Recruiting NCT05372614 - Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene Phase 1

External Links